A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Summary

The reason for this study is to see if the CD73 inhibitor HLX23 alone is safe and effective in participants with advanced solid cancer.

Timeline

Start

2022-07-18

Primary completion

2023-01-13

Completion

2023-01-13

Outcome

Outcome not reported

Stopped: “The Early Termination is the result of the sponsor's need to reevaluate the study design and to make needed vendor realignments.”

Drugs

Indications